Pharmacosmos’ Monoferric 1000 mg IV Receives Health Canada Marketing Approval

Shots:

•  Monoferric is being approved for anaemic adult patients intolerant or unresponsive to iron oral therapy with an expection to reach market by Nov 2018
• In 2015, Pharmacosmos signed Canada commercialization rights of Monoferric to Pfizer Canada
• Monoferric IV has a novel matrix structure of linear isomaltoside chains interspersed with Fe3+ and already being marketed in >30 countries worldwide

Click here to read full press release/ article | Ref: Pharmacosmos | Image:  Pharmacosmos